Back to top

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 ...

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy | PRTA Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Prothena Corporation plc (PRTA)